SalusPharma announced that it has completed a Series A financing round, raising tens of millions of yuan. The round was co-invested by Kaitai Capital and Zhongnan Capital.
SalusPharma was established in the United States in December 2010. The company specializes in the development and innovation of pharmaceutical processes and drug delivery technologies to develop and manufacture derivative new drugs and innovative drugs.
The company uses its unique osmotic pump sustained release technology and pellet controlled release expertise to develop NDA and ANDA drugs. The core founding team has more than 20 years of work experience in pharmaceutical R&D, process development, drug production, and drug registration.
At present, the company's product pipeline is centered on osmotic pump technology-based sustained and controlled release preparations. It has established a unique osmotic pump and pellet controlled release technology platform. SalusPharma has more than 10 products in development, mainly covering the treatment ofchronic diseases such as hypertension, diabetes and others.